>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们在线留言
最新消息:
SIRT3在乳腺癌中的表达与临床预后的相关性分析
作者:王峰  李梅  朱建伟  茅国新 
单位:南通大学附属医院 肿瘤化疗科, 江苏 南通 226001
关键词:乳腺癌 SIRT3 预后 
分类号:R737.9
出版年·卷·期(页码):2017·36·第四期(524-529)
摘要:

目的:探讨乳腺癌患者癌组织中SIRT3表达与临床特征和预后之间的相关性。方法:回顾性收集南通大学附属医院2010年1月至2015年6月250例经病理检查证实为乳腺癌女性患者的临床资料,运用免疫组化法检测癌组织中SIRT3的表达水平,并分析其与患者临床、病理资料和总生存期的关系。结果:肿瘤≥2 cm,淋巴结转移,组织学Ⅱ级、Ⅲ级,小叶癌,PR受体阴性,Her2受体阴性情况下SIRT3呈现高表达比例均较高,差异有统计学意义(均P<0.05)。多因素Cox回归分析显示,肿瘤大小、淋巴结转移以及SIRT3表达是影响总生存时间的独立影响因素。SIRT3低表达组中位生存时间为43个月(95%CI为41.24~44.75),SIRT3高表达组中位生存时间为29个月(95%CI为28.83~31.17),两组差异有统计学意义(P=0.005)。结论:SIRT3蛋白可作为一个评价乳腺癌患者预后的重要指标及潜在治疗靶标。

Objective:To investigate the correlation between SIRT3 expression and clinical features and prognosis in patients with breast cancer. Methods:The clinical data of 250 female patients with breast cancer were collected and analyzed retrospectively from January 2010 to June 2015. The expression of SIRT3 in tumor tissues was detected using immunohistochemical method, and the relationship between the clinical data and the overall survival of patients was analyzed. Results:Tumors whose size larger than 2 cm with lymph node metastasis, histological grade Ⅱ and Ⅲ, lobular carcinoma and negative PR receptors were associated with the high expression level of SIRT3 with a significant difference(P<0.05). Multiple Cox regression analysis showed that age, menstruation, lymph node metastasis and SIRT3 expression were independent factors affecting overall overall survival. The median survival time was 43 months (95%CI:41.24-44.75) in the SIRT3 low expression group, and 29 months (95%CI:28.83-31.17) in the SIRT3 high expression group, with a statistically significant difference (P=0.005). Conclusion:SIRT3 protein can be used as an important index and potential therapeutic target in the diagnosis and evaluating prognosis of breast cancer patients.

参考文献:

[1] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10.
[2] WANG Q,LI L,LI C Y,et al.SIRT3 protects cells from hypoxia via PGC-1α-and MnSOD-dependent pathways[J].Neuroscience,2015,12(286):109-121.
[3] CLAYCOMBE K J,ROEMMICH J N,JOHNSON L,et al.Skeletal muscle Sirt3 expression and mitochondrial respiration are regulated by a prenatal low-protein diet[J].J Nutr Biochem,2015,26(2):184-189.
[4] 翟雅娜.MK、p53、bcl-2在乳腺癌患者中的表达及其相关性分析[J].现代医学,2016,44(12):1702-1705.
[5] SONG Y,SHI J,WU Y,et al.Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3[J].Chin Med J(Engl),2014,127(8):1523-1529.
[6] BAO J,LU Z,JOSEPH J J,et al.Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms[J].J Cell Biochem,2010,110(1):238-247.
[7] TEODORO J S,DUARTE F V,GOMES A P,et al.Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats:a possible role for SirT3 activation[J].Mitochondrion,2013,13(6):637-646.表3乳腺癌患者OS单因素Cox回归分析Tab 3 Singl Cox regression analysis of OS in patients with breast cancer临床特征偏回归系数标准误P值HR(95%CI)年龄(1=<45岁,2= ≥ 45岁)0.160.1210.0571.18(0.88~2.42)月经(1=未绝经,2=绝经)0.140.2060.4911.15(0.77~1.73)肿瘤大小(1=<2 cm,2= ≥ 2 cm)1.660.240<0.0015.24(3.27~8.39)淋巴结转移(1=无,2=有)4.270.535<0.00171.49(25.05~204.07)组织学分级(Ⅰ=1,Ⅱ、Ⅲ=2)2.670.256<0.00114.39(8.71~23.76)病理组织分型(1=导管癌,2=小叶癌)-3.400.447<0.0010.34(0.01~0.08)ER(1=阴性,2=阳性)2.830.297<0.00116.99(9.49~30.41)PR(1=阴性,2=阳性)-2.670.273<0.0010.07(0.04~0.12)Her-2(1=阴性,2=阳性)-2.680.258<0.0010.06(0.03~0.10)SIRT3表达(1=低表达,2=高表达)0.620.2220.0051.87(1.21~2.88)表4乳腺癌患者OS多因素Cox回归分析Tab 4 Multiple Cox regression analysis of OS in patient with breast cancer临床特征偏回归系数标准误P值HR(95%CI)肿瘤大小(1=<2 cm,2= ≥ 2 cm)3.511.2940.0133.60(2.66~424.42)淋巴结转移(1=无,2=有)1.360.8660.013.91(1.13~9.36)SIRT3表达(1=低表达,2=高表达)0.700.3180.032.00(1.07~3.74)图2 SIRT3高表达组和低表达组的乳腺癌患者生存分析Fig 2 Analysis of OS between SIRT3 high expression group and SIRT3 low expression group
[8] DRANSFELD C L,ALBORZINIA H,WOLFL S,et al.SIRT3 SNPs validation in 640 individuals,functional analyses and new insights into SIRT3 stability[J].Int J Oncol,2010,36(4):955-960.
[9] DISCH J S,EVINDAR G,CHIU C H,et al.Discovery of thieno[3,2-d] pyrimdine-6-carboxamides as potent inhibitors of SIRT1,SIRT2,and SIRT3[J].J Med Chem,2013,56(9):3666-3679.
[10] LIU T F,VACHHARAJANI V,MILLET P,et al.Sequential actions of SIRT1-RELB SIRT3 coordinate nuclear-mitochondrial communication during immunometabolic adaptation to acute inflammation and sepsis[J].J Biol Chem,2015,290(1):396-408.
[11] 李利娟,张景华,魏丽娟,等.43例分泌性乳腺癌临床分析[J].中华普通外科杂志,2014,29(9):684-687.
[12] 李生兰,纪少春,栾宏辉,等.早期乳腺癌患者术后放化疗后不同基因分型的预后分析[J].现代肿瘤医学,2015,23(2):225-228.
[13] 罗舟,徐涛,秦建伟,等.前哨淋巴结活组织检查指导乳腺癌腋窝淋巴结清扫问题的思考[J].中华乳腺病杂志:电子版,2014,12(1):55-58.
[14] 石琴芳,冯梦宇,罗琨,等.乳腺癌组织Ras相关区域家族1A基因启动子甲基化状态及临床意义[J].中华实验外科杂志,2015,32(1):154-156.
[15] 刘海芳,高杨,姜楠,等.乳腺癌超声表现与生物学指标的相关性及对临床治疗的指导意义[J].中国医药,2015,10(1):1-4.
[16] HE S,HE C,YUAN H,et al.The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients[J].Cell Physiol Biochem,2014,34(6):2061-2069.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 118079 位访问者

copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232483 83272481
电子邮件: bjb@pub.seu.edu.cn